Kim Allman

@shilpaonc @BladderCancerUS @CleClinicMD @ClevelandClinic @PGrivasMDPhD @DrOmarMian @GeneCollector @MosheOrnsteinMD @ChrisWeeMD @AmandaNizamMD @caseccc @CleClinicUro @LauraBukavinaMD Ha! That’s great!

#Halloween #MarcelaDiaz #HenryBoyes as EV Pembro, the hit combo in UC! @CleClinicMD @ClevelandClinic @PGrivasMDPhD @DrOmarMian

📸 Learning from @kidneycancerdoc at #worldgu25 on imaging for kidney masses. Novel modalities on the horizon, including CAIX-PSMA, with the FDA set to weigh in next week 🔬💡 Exciting times for #RCC care! #kidneycancer #GUonc

@montypal @JasnoorMalhotra @UCRiverside @DrChoueiri @VivekSubbiah @timir_paul @neerajaiims @PGrivasMDPhD @rachnatshroff @ReginaBarCar @NazliDizman @DrRaviSalgia @cityofhope Awesome story!

An #ASCO25 Poster Session Story: The story begins in 2020, when @JasnoorMalhotra (a @UCRiverside graduate) babysat for my kids for an afternoon (picture below from 5y ago!). Her mom was my kids AMAZING preschool teacher. Jasnoor expressed interest in going to #medschool & wanted to get some research experience. I invited her to join my group (1/6) ...

Juravinski/Walker Cancer Centres Forum 2025 @CanUrolAssoc Excellent presentation by Kimberly Allman of Telix on Novel Theranostics - a diagnostic agent. Not in Canada yet but hopefully coming soon! #kidneycancer @KidneyCancer_Ca @CancerduRein

The U.S. FDA has accepted Telix’sBiologics License Application (BLA) for its investigational kidney cancer imaging agent TLX250-CDx (Zircaix®, 89Zr-DFO-girentuximab), granting a Priority Review with a PDUFA date of August 27, 2025. This acceptance brings this breakthrough product one step closer to patients and paves the way for a U.S. commercial launch in 2025. If approved, TLX250-CDx will become the first commercially available imaging agent to accurately and non-invasively diagnose and characterize clear cell renal cell carcinoma (ccRCC), the most common and one of the most aggressive sub-types of kidney cancer. Read more on our website here: telixpharma.com/news-views/fda…

@katy_beckermann Congratulations, Katy! They are so lucky to have you.

After 20 wonderful years at Vanderbilt 🏫🔬, I’m grateful for the mentorship & colleagues that shaped my journey 🙏. Excited to start as Medical Director for GU Clinical Research at Tennessee Oncology & Greco-Hainsworth Centers 💊🧪, bringing trials & care to patients across TN

Telix today announces that it has submitted its Biologics License Application (BLA) to the U.S. FDA for TLX250-CDx (Zircaix®, 89Zr-girentuximab) kidney cancer imaging. TLX250-CDx is an investigational PET drug product for the non-invasive diagnosis and characterisation of clear cell renal cell carcinoma (ccRCC), the most common and aggressive form of kidney cancer. If approved, TLX250-CDx will be the first and only targeted PET agent specifically for kidney cancer to be commercially available in the U.S., further building on Telix’s successful urology imaging franchise. Read more on our website here: telixpharma.com/news-views/tel… TLX250-CDx has not received a marketing authorisation in any jurisdiction.

Today marked an important milestone for Telix as we commenced trading on the @Nasdaq under the ticker “TLX”. We reaffirm our founding commitment to building a world-class global business, that delivers on the promise of precision medicine through targeted radiation, helping people with cancer and rare diseases live longer, better quality lives. Listing on Nasdaq is key towards achieving these goals, and an appropriate step given our growth trajectory, leadership position in radiopharmaceuticals and expanding footprint in North America. We would like to thank the many who have helped us reach this point. Read more on our website here: bit.ly/4fNWEdY This does not constitute an offer to sell or the solicitation of an offer to buy any securities of Telix.

@kaydaustin Congratulations, Katie!

Release day is officially here!!! 🎉 I put my heart and soul into this book to share an honest and raw perspective of what it was like to battle an ultra rare stage IV kidney cancer at 29. I can’t believe release day has finally arrived and I feel so incredibly grateful to still be here to watch it come to life. I hope you enjoy the read!

Just in @MedCellPress 👉Excellent viewpoint by our trainee, Chadi @chadihc98 👉The novel Zirconium-girentuximab PET-CT is set to change the diagnostic paradigm of ccRCC #kidneycancer (akin to PSMA-PET in #prostatecancer)👇 bit.ly/48LBPgB @ggebraelmd @urotoday @OncoAlert

@MosheOrnsteinMD @shilpaonc @CleClinicMD @PBarataMD @caseccc @Browns Very cool!

⁦⁦@shilpaonc⁩ ⁦⁦@CleClinicMD⁩ and ⁦@PBarataMD⁩ ⁦@caseccc⁩ kicking off the first annual Cleveland GU Oncology consortium at ⁦@Browns⁩ stadium!

Out today in @TIME — a review of recent advances in #KidneyCancer treatment highlighting the incredible work of @DrChoueiri @DanaFarber_GU @brian_rini @VUMCHemOnc @UroWCH @nyulmc @Katie_Spina @ColumbiaRadOnc @schadegr @fredhutch and many others! It takes a village to #AccelerateCures for #RCC, and our village is strong 💪 🔗 bit.ly/RCC_Advances

@ZakhariaYousef @IMG_Oncologists Congratulations, Yousef!

22 yrs ago, purchased my 1st English medical textbook with English-Arabic dictionary as we studied medicine in Arabic 20 yrs ago, my 1st trip to US to improve my English Today Professor of Medicine! Many ups and downs in between, let alone visa issues What a Journey! V Thankful

@ThirdEyeBlind @Mandelicatessen!!

Tag your Summer Gods travel companion for a chance to win a signed tour poster.

@shilpaonc @jamecancerdoc Congratulations, Shilpa!! So well deserved!!

Thanks @jamecancerdoc for all your support always! Grateful for your kindness and leadership!

@koshkin85 @UCSF @UCSFMedicine @UCSFCancer @PGrivasMDPhD @GUONCGarciaJA @brian_rini @neerajaiims @montypal @charlesryanmd @SimaPorten @thomashopemd @AlvaAjjai @drkomanduri @PBarataMD @arnabguonc @Tanjin097 @AmandaNizamMD @arkhaki @DrOmarMian @OAlhalabiMD @DocMattCampbell @DrTFriedlander @shilpaonc Congratulations, Vadim!!

Finally posting about recent promotion to Associate Professor @UCSF @UCSFMedicine Appreciate the support of so many to help me get here @ucsfcancer @PGrivasMDPhD @GUONCGarciaJA @brian_rini @neerajaiims @montypal @charlesryanmd @SimaPorten @thomashopemd @AlvaAjjai @drkomanduri

@shilpaonc Enjoy, Shilpa! 😎

Glad to be in #Cleveland for #SolarEclipse2024 Hoping to see the #totality

@shilpaonc @CleClinicMD @Uromigos @tompowles1 @MichvdHeijden @MosheOrnsteinMD @AmandaNizamMD @ChrisWeeMD @n8pennell @jamecancerdoc @caseccc @BladderCancerUS Amazing story! Wonderful news!

An indescribable, overwhelming feeling to see our 1st pt on EV Pembro on EV-302 w/ ongoing CR since the 1st scan ~ 3 yrs ago! He has traveled to over 20 countries across 5 continents while on tx. Grateful to our wonderful team @CleClinicMD for making this study a huge success!

@KunalDesaiMD @abbvie Congratulations, Kunal!

@MosheOrnsteinMD Go MO!

11/8 ✅